Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Aug. 31, 2014	Aug. 31, 2013
Net sales	$ 774.8	$ 730.7
Cost of sales	215.9	208.0
Gross profit	558.9	522.7
Selling, general and administrative expense	361.7	313.3
Research and development expense	42.8	37.5
Amortization	71.9	75.5
Operating income	82.5	96.4
Interest expense	80.1	87.6
Other (income) expense	(4.2)	2.2
Other expense, net	75.9	89.8
Income before income taxes	6.6	6.6
Benefit from income taxes	(0.7)	(24.5)
Net income	7.3	31.1
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available-for-sale securities	0.1	0
Interest rate swap unrealized gains (losses)	3.6	13.5
Foreign currency related gains (losses)	(48.2)	4.5
Unrecognized actuarial gains (losses)	0.3	0.2
Other comprehensive income (loss)	(44.2)	18.2
Comprehensive income (loss)	(36.9)	49.3
Biomet, Inc. [Member]
Net sales	774.8	730.7
Cost of sales	215.9	208.0
Gross profit	558.9	522.7
Selling, general and administrative expense	361.7	313.3
Research and development expense	42.8	37.5
Amortization	71.9	75.5
Operating income	82.5	96.4
Interest expense	80.1	87.6
Other (income) expense	(4.2)	2.2
Other expense, net	75.9	89.8
Income before income taxes	6.6	6.6
Benefit from income taxes	(0.7)	(24.5)
Net income	7.3	31.1
Other comprehensive income (loss), net of tax:
Change in unrealized holding value on available-for-sale securities	0.1	0
Interest rate swap unrealized gains (losses)	3.6	13.5
Foreign currency related gains (losses)	(48.2)	4.5
Unrecognized actuarial gains (losses)	0.3	0.2
Other comprehensive income (loss)	(44.2)	18.2
Comprehensive income (loss)	$ (36.9)	$ 49.3